This brand name is authorized in Malta
The drug DABAHIB contains one active pharmaceutical ingredient (API):
|
1
Dabigatran
UNII 2E18WX195X - DABIGATRAN ETEXILATE
|
|
Dabigatran etexilate is a small molecule prodrug which does not exhibit any pharmacological activity. After oral administration, dabigatran etexilate is rapidly absorbed and converted to dabigatran by esterase-catalysed hydrolysis in plasma and in the liver. Dabigatran is a potent, competitive, reversible direct thrombin inhibitor and is the main active principle in plasma. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| B01AE07 | Dabigatran etexilate | B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AE Direct thrombin inhibitors |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: MT | Medicines Authority | Identifier(s): MA993/00701, MA993/00702, MA993/00703 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
